SEC Form 4 · accession 0000904454-18-000341
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim P. Kamdar
Director
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.99 | May 8, 2018 | A | 12,875 | A | — | May 8, 2028 | Common Stock | 12,875 | 12,875 | D |
Explanation of responses
- F1The option vests in full on May 8, 2019, subject to the Reporting Person's continuous service to the Issuer.